HCW Biologics is trading 8.1% up at $3.61 as traders continue to respond to significant insider buying by CEO Hing Wong.
- The move extends a sharp rally that began after a July 29 disclosure revealed Wong purchased shares at $2.59.
- The insider activity is being interpreted as a strong confidence signal, driving ongoing momentum for the stock.
- Gains are further supported by a generally risk-on broader market backdrop.